The emerging role of m6A in aortic dissection: from molecular mechanisms to therapeutic potential
- 1The First Affiliated Hospital, Department of Cardiothoracic Surgery, Hengyang Medical School, University of South China, Hengyang, Hunan, China
- 2Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China
Abstract
Aortic dissection (AD) is an emergent medical condition with a hidden onset and sudden rupture, which usually results in a high mortality rate. N6-methyladenosine (m6A) is the most abundant modification in eukaryotic RNA molecules and plays a critical role in regulating RNA metabolism. Dysregulation of m6A modification has been linked to a variety of diseases. Interestingly, aberrant expression of m6A-associated factors is observed in AD. The m6A methylation can promote or inhibit the development of AD by modulating cell death, oxidative stress, macrophage polarization and VSMC phenotype switching, depending on m6A-modified transcripts, readers and downstream pathways. In addition, m6A exerts a significant effect on the major risk factors for AD, including hypertension, atherosclerosis, obesity and aortic aneurysm. Thus, modulating m6A modification by small-molecule inhibitors, natural products or miRNAs may represent a promising approach for developing new therapeutic interventions for AD. In this review, we first give a brief perspective on m6A modification and its regulators. Subsequently, we summarize the recent research progress on the role of m6A in AD and related-risk factors, with an emphasis on its diagnostic value and therapeutic potential.
Related
- The Role of Neutrophil Extracellular Traps (NETosis) in Systemic Lupus Erythematosus: Molecular Mechanisms, Pathogenic Roles, Diagnostic Biomarkers, and Emerging Therapeutic Strategies
- Emerging roles of m6A in female reproductive disorders: from molecular mechanisms to therapeutic targets
- The m6A methyltransferase METTL3 in intervertebral disc degeneration: from molecular mechanisms to therapeutic potential
- Migrasomes in kidney diseases: emerging molecular mechanisms, diagnostic value, and therapeutic prospects.
- Natural Inhibitors of 5-Alpha Reductase: Mechanisms, Therapeutic Potential, and Emerging Perspectives in Androgen-Dependent Prostate Disorders
BibTeX
@article{she2026emerging,
title = {{The emerging role of m6A in aortic dissection: from molecular mechanisms to therapeutic potential}},
author = {Cheng-Qun She and Chong-Zhong Long and Xiao-Lin Lyv and Zheng-Weng Lei and Wen-An Kuang and Hao Deng and Mei-Ling Yi and Shi-Wei Cai and Xiao-Hua Yu and Yuan Peng and Yao-Guang Feng},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
month = oct,
doi = {10.3389/fcell.2026.1906074},
url = {https://doi.org/10.3389/fcell.2026.1906074},
note = {CC BY},
}
RIS
TY - JOUR
TI - The emerging role of m6A in aortic dissection: from molecular mechanisms to therapeutic potential
AU - Cheng-Qun She
AU - Chong-Zhong Long
AU - Xiao-Lin Lyv
AU - Zheng-Weng Lei
AU - Wen-An Kuang
AU - Hao Deng
AU - Mei-Ling Yi
AU - Shi-Wei Cai
AU - Xiao-Hua Yu
AU - Yuan Peng
AU - Yao-Guang Feng
PY - 2026
DA - 2026/10/23
JO - Frontiers in Cell and Developmental Biology
DO - 10.3389/fcell.2026.1906074
UR - https://doi.org/10.3389/fcell.2026.1906074
AB - Aortic dissection (AD) is an emergent medical condition with a hidden onset and sudden rupture, which usually results in a high mortality rate. N6-methyladenosine (m6A) is the most abundant modification in eukaryotic RNA molecules and plays a critical role in regulating RNA metabolism. Dysregulation of m6A modification has been linked to a variety of diseases. Interestingly, aberrant expression of m6A-associated factors is observed in AD. The m6A methylation can promote or inhibit the development of AD by modulating cell death, oxidative stress, macrophage polarization and VSMC phenotype switching, depending on m6A-modified transcripts, readers and downstream pathways. In addition, m6A exerts a significant effect on the major risk factors for AD, including hypertension, atherosclerosis, obesity and aortic aneurysm. Thus, modulating m6A modification by small-molecule inhibitors, natural products or miRNAs may represent a promising approach for developing new therapeutic interventions for AD. In this review, we first give a brief perspective on m6A modification and its regulators. Subsequently, we summarize the recent research progress on the role of m6A in AD and related-risk factors, with an emphasis on its diagnostic value and therapeutic potential.
SN - 2296-634X
ER -